Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective

Statistical Methods in Medical Research

Volumn 17, Issue 5, 2008, Pages 529-535

  Grothey, Axel ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DOCTOR PATIENT RELATION; DRUG CHOICE; DRUG EFFICACY; EARLY CANCER; HUMAN; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; OVERALL SURVIVAL; SURVIVAL TIME;

ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; HUMANS; SURVIVAL ANALYSIS;

EID: 52649088322     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280207081853     Document Type: Conference Paper

References (14)

1. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. The New England Journal of Medicine 1990; 322: 352-8.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. Journal of Clinical Oncology 1995; 13: 2936-43.
3. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. Journal of Clinical Oncology 2005; 23: 8671-8.
4. Andre T., Colin P., Louvet C., Gamelin E., Bouche O., Achille E., Colbert N., Boaziz C., Piedbois P., Tubiana-Mathieu N., Boutan-Laroze A., Flesch M., Buyse M., de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. Journal of Clinical Oncology 2003; 21: 2896-903.
5. Twelves C., Wong A., Nowacki MP, Abt M., Burris H., 3rd, Carrato A., Cassidy J., Cervantes A., Fagerberg J., Georgoulias V., Husseini F., Jodrell D., Koralewski P., Kroning H., Maroun J., Marschner N., McKendrick J., Pawlicki M., Rosso R., Schuller J., Seitz JF, Stabuc B., Tujakowski J., Van Hazel G., Zaluski J., Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. The New England Journal of Medicine 2005; 352: 2696-704.
6. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England Journal of Medicine 2004; 350: 2343-51.
7. Wolmark N., Wieand HS, Kuebler J., Colangelo L., Smith R. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. Journal of Clinical Oncology 2005; 23: LBA3500 [abstr].
8. Van Cutsem E., Labianca R., Hossfeld DK, Bodoky G., Roth A., Aranda E., Nordlinger B., Assadourian S., Wang K., Cunningham D. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Journal of Clinical Oncology 2005; 23: LBA8 [abstr].
9. Ychou M., Raoul J., Douillard JY, Bugat R., Mineur L., Viret F., Becouarn Y., Bouche O., Jacob J., Gourgou-Bourgade S. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Journal of Clinical Oncology 2005; 23: 3502 [abstr].
10. de Gramont A., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., Bonetti A., Clingan P., Marceau-Suissa J., Lorenzato C., Andre T. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Journal of Clinical Oncology 2005; 23: 3501 [abstr].
11. Sargent DJ, Wieand HS, Haller DG, Gray R., Benedetti JK, Buyse M., Labianca R., Seitz JF, O'Callaghan CJ, Francini G., Grothey A., O'Connell M., Catalano PJ, Blanke CD, Kerr D., Green E., Wolmark N., Andre T., Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology 2005; 23: 8664-70.
12. Baker SG, Kramer BS A perfect correlate does not a surrogate make. BMC Medical Research Methodology 2003; 3: 16.
13. Goldberg RM, Rothenberg ML, Van Cutsem E., Benson AB, 3rd, Blanke CD, Diasio RB, Grothey A., Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R., Armstrong D., Viele C. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38-50.
14. Grothey A., Sargent D., Goldberg RM, Schmoll HJ Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Journal of Clinical Oncology 2004; 22: 1209-14.